tradingkey.logo
搜尋

Emergent BioSolutions Inc

EBS
添加自選
8.280USD
+0.010+0.12%
收盤 07/02, 13:00美東報價延遲15分鐘
428.90M總市值
虧損本益比TTM

Emergent BioSolutions Inc

8.280
+0.010+0.12%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.12%

5天

-2.93%

1月

-1.90%

6月

-33.81%

今年開始到現在

-33.01%

1年

+18.45%

關鍵數據
8.390今開
8.530最高
575.96K成交量
虧損本益比TTM
--本益比動
--股利TTM
1.11%換手率
8.280昨收
8.115最低
2.22M成交額
虧損本益比靜
0.82市淨率
0.00%股息率 TTM
-0.63%ROA
14.06052週最高
1.04量比
-190.60M淨利潤
51.80M總股本
-0.1358每股盈餘TTM
2.34Beta
-1.60%ROE
5.61552週最低
5.01%振幅
53.88%毛利率
428.90M總市值
-0.47回報/風險
3.99%風險率

TradingKey Emergent BioSolutions Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Emergent BioSolutions Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名62/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為12.00。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Emergent BioSolutions Inc評分

相關信息

行業排名
62 / 157
全市場排名
148 / 4565
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Emergent BioSolutions Inc亮點

亮點風險
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值低估
公司最新PE估值-60.97,處於3年歷史低位
機構減倉
最新機構持股42.30M股,環比減少7.38%
ETHSX持倉
明星投資者ETHSX持倉,最新持倉233.33K股

分析師目標

基於 2 分析師
買入
評級
12.000
目標均價
+44.93%
漲幅空間

Emergent BioSolutions Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Emergent BioSolutions Inc簡介

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
公司代碼EBS
公司Emergent BioSolutions Inc
CEOPapa (Joseph C)
網址https://emergentbiosolutions.com/

常見問題

Emergent BioSolutions Inc(EBS)的當前股價是多少?

Emergent BioSolutions Inc(EBS)的當前股價是 8.28。

Emergent BioSolutions Inc 的股票代碼是什麼?

Emergent BioSolutions Inc的股票代碼是EBS。

Emergent BioSolutions Inc股票的52週最高點是多少?

Emergent BioSolutions Inc股票的52週最高點是14.06。

Emergent BioSolutions Inc股票的52週最低點是多少?

Emergent BioSolutions Inc股票的52週最低點是5.62。

Emergent BioSolutions Inc的市值是多少?

Emergent BioSolutions Inc的市值是428.90M。

現在Emergent BioSolutions Inc(EBS)的股票是買入、持有還是賣出?

根據分析師評級,Emergent BioSolutions Inc(EBS)的總體評級為買入,目標價格為12.00。

Emergent BioSolutions Inc(EBS)股票的每股收益(EPS TTM)是多少

Emergent BioSolutions Inc(EBS)股票的每股收益(EPS TTM)是0.98。